Prof. Dr. med. Alexander Drzezga - Curriculum Vitae

Education and professional career

since 2012: Professor and Chair, Department of Nuclear Medicine, University of Cologne
2011 - 2012: W2-Heisenberg-Professor for Multimodal Imaging in Neurodegenerative Disorders, Technical University of Munich (TUM)
2009 - 2010: Visiting Professor at Harvard Medical School (Heisenberg fellow), Massachusetts General Hospital, Athinoula A. Martinos Center for Biomedical Imaging, Boston, USA
2005 - 2012: Assistant Professor for Nuclear Medicine, TUM
2002 - 2012: Consultant for Nuclear Medicine, Department of Nuclear Medicine, TUM
2002: Board Certification for Nuclear Medicine
1997 - 2002: Residency, Department of Nuclear Medicine, TUM
1997: Step 2 of the USMLE (United States Medical Licensing Examination)
1996: German State Medical Examination and Medical License
1994: Step 1 of the USMLE

Awards, distinctions and professional activities

since 2017: Director of the Brain Imaging Council, Board of Directors, Society of Nuclear Medicine and Molecular Imaging (SNMMI)
since 2015: Chairman of the Ethics Committee, University of Cologne
since 2015: Executive board member of the German Society for Nuclear Medicine (DGN)
2013 - 2017: Chair of the Scientific Program Committee for Molecular Imaging, Radiological Society of North America (RSNA)
since 2013: Member of the Neuroimaging Council (NIC) of the European Association for Nuclear Medicine (EANM)
2013 - 2016: Chair of the Committee for Diagnosis-Related Group Systems (DRG) and activity recording, German Society for Nuclear Medicine (DGN)
2012: Editor’s Choice Award of the Journal of Nuclear Medicine 2012
2010: ‘Hiruma-Wagner Award’ of the Research Foundation for Opto-Science and Technology
2008: ‘Heisenberg-Grant’ of the German Research Foundation (DFG)
2006: ‘The Alzheimer’s Disease Neuroimaging Award’ of the International Alzheimer’s Association

Selected publications

Hoenig MC, Bischof GN, Hammes J, Faber J, Fliessbach K, van Eimeren T, Drzezga. A. Tau pathology and cognitive reserve in Alzheimer's disease. Neurobiol Aging. 2017 May 10;57:1-7. doi: 10.1016/j.neurobiolaging.

Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, Schomäcker K, Heidenreich A, Zlatopolskiy BD, Neumaier B, Drzezga A, Dietlein M. PSA-Stratified Performance of (18)F- and (68)Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. J Nucl Med. 2017 Jun;58(6):947-952. doi: 10.2967/jnumed.116.185538.

Tahmasian M, Pasquini L, Scherr M, Meng C, Förster S, Mulej Bratec S, Shi K, Yakushev I, Schwaiger M, Grimmer T, Diehl-Schmid J, Riedl V, Sorg C, Drzezga A. The lower hippocampus global connectivity, the higher its local metabolism in Alzheimer disease. Neurology. 2015, Apr 15.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ; Amyloid PET Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015, May 19;313(19):1939-49. doi: 10.1001/jama.2015.4669.

Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S,  mthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A,  Dietlein M. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. J Clin Oncol. 2014, Jun 10;32(17):1776-81. doi: 10.1200/JCO.2013.53.2507.

Koch K, Myers NE, Göttler J, Pasquini L, Grimmer T, Förster S, Manoliu A, Neitzel J, Kurz A, Förstl H, Riedl V, Wohlschläger AM, Drzezga A and Sorg C. Disrupted Intrinsic Networks Link Amyloid-ß Pathology and Impaired Cognition in Prodromal Alzheimer's Disease. Cereb Cortex. 2014, Jul 4. pii: bhu151.

Riedl V, Bienkowska K, Strobel C, Tahmasian M, Grimmer T, Förster S, Friston KJ, Sorg C and Drzezga A. Local activity determines functional connectivity in the resting human brain: a simultaneous FDG-PET/fMRI study. J Neurosci. 2014 Apr 30;34(18):6260-6.

Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, Neitzel J, Mühlau M, Förster S, Kurz A, Förstl H, Zimmer C, Wohlschläger AM, Riedl V, Drzezga A and Sorg C. Within-patient correspondence of amyloid-ß and intrinsic network connectivity in Alzheimer's disease. Brain. 2014, Jul;137(Pt7):2052-64.

Förster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, Wester HJ, Förstl H, Kurz A, Dickerson BC, Bartenstein P, Drzezga A. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry. 2012, May 1;71(9):792-7.

Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S, Voss A, Huisman M, Settles M, Neff F, Velden J, Schoor M, von der Kammer H, Wester HJ, Schwaiger M, Henriksen G, Drzezga A. Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One. 2012, 7(3):e31310. doi: 10.1371/journal.pone.0031310.

Drzezga A, Becker JA, Van Dijk KR, Sreenivasan A, Talukdar T, Sullivan C, Schultz AP, Sepulcre J, Putcha D, Greve D, Johnson KA, Sperling RA. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011, Jun;134(Pt 6):1635-46.

Drzezga A, Grimmer T, Peller M, Wermke M, Siebner H, Rauschecker JP, Schwaiger M, Kurz A. Impaired cross-modal inhibition in Alzheimer disease. PLoS Med. 2005, Oct;2(10):e288.